vs
Magnera Corp（MAGN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Magnera Corp的季度营收约是Revvity的1.0倍（$792.0M vs $772.1M），Revvity净利率更高（12.7% vs -4.3%，领先17.0%），Magnera Corp同比增速更快（12.8% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-13.0M），过去两年Magnera Corp的营收复合增速更高（54.9% vs 9.0%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MAGN vs RVTY — 直观对比
营收规模更大
MAGN
是对方的1.0倍
$772.1M
营收增速更快
MAGN
高出7.0%
5.9%
净利率更高
RVTY
高出17.0%
-4.3%
自由现金流更多
RVTY
多$174.8M
$-13.0M
两年增速更快
MAGN
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $792.0M | $772.1M |
| 净利润 | $-34.0M | $98.4M |
| 毛利率 | 12.2% | — |
| 营业利润率 | 1.8% | 14.5% |
| 净利率 | -4.3% | 12.7% |
| 营收同比 | 12.8% | 5.9% |
| 净利润同比 | 43.3% | 3.9% |
| 每股收益（稀释后） | $-0.95 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAGNRVTY
| Q4 25 | $792.0M | $772.1M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | $839.0M | $720.3M | ||
| Q1 25 | $824.0M | $664.8M | ||
| Q4 24 | $702.0M | $729.4M | ||
| Q3 24 | $332.1M | $684.0M | ||
| Q2 24 | $556.0M | $691.7M | ||
| Q1 24 | $558.0M | $649.9M |
净利润MAGNRVTY
| Q4 25 | $-34.0M | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | $-18.0M | $53.9M | ||
| Q1 25 | $-41.0M | $42.2M | ||
| Q4 24 | $-60.0M | $94.6M | ||
| Q3 24 | $-15.2M | $94.4M | ||
| Q2 24 | $19.0M | $55.4M | ||
| Q1 24 | $14.0M | $26.0M |
毛利率MAGNRVTY
| Q4 25 | 12.2% | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | 10.7% | 54.5% | ||
| Q1 25 | 10.7% | 56.5% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 10.7% | 56.3% | ||
| Q2 24 | 6.6% | 55.7% | ||
| Q1 24 | 6.2% | 54.6% |
营业利润率MAGNRVTY
| Q4 25 | 1.8% | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 1.5% | 12.6% | ||
| Q1 25 | 0.5% | 10.9% | ||
| Q4 24 | -3.1% | 16.3% | ||
| Q3 24 | 0.9% | 14.3% | ||
| Q2 24 | 3.1% | 12.4% | ||
| Q1 24 | 3.8% | 6.8% |
净利率MAGNRVTY
| Q4 25 | -4.3% | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | -2.1% | 7.5% | ||
| Q1 25 | -5.0% | 6.4% | ||
| Q4 24 | -8.5% | 13.0% | ||
| Q3 24 | -4.6% | 13.8% | ||
| Q2 24 | 3.4% | 8.0% | ||
| Q1 24 | 2.5% | 4.0% |
每股收益（稀释后）MAGNRVTY
| Q4 25 | $-0.95 | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | $-0.51 | $0.46 | ||
| Q1 25 | $-1.15 | $0.35 | ||
| Q4 24 | $-1.69 | $0.77 | ||
| Q3 24 | $-0.33 | $0.77 | ||
| Q2 24 | $0.60 | $0.45 | ||
| Q1 24 | $0.44 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $264.0M | $919.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $3.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.86× | — |
8季度趋势，按日历期对齐
现金及短期投资MAGNRVTY
| Q4 25 | $264.0M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | $276.0M | $991.8M | ||
| Q1 25 | $282.0M | $1.1B | ||
| Q4 24 | $215.0M | $1.2B | ||
| Q3 24 | $230.0M | $1.2B | ||
| Q2 24 | $33.9M | $2.0B | ||
| Q1 24 | $30.2M | $1.7B |
总债务MAGNRVTY
| Q4 25 | $1.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $877.4M | — | ||
| Q1 24 | $884.7M | — |
股东权益MAGNRVTY
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.4B | $7.8B |
总资产MAGNRVTY
| Q4 25 | $3.9B | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | $4.1B | $12.4B | ||
| Q1 25 | $4.1B | $12.4B | ||
| Q4 24 | $4.0B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $1.5B | $13.4B | ||
| Q1 24 | $1.5B | $13.4B |
负债/权益比MAGNRVTY
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.77× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 1.80× | — | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-13.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流MAGNRVTY
| Q4 25 | $2.0M | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | $0 | $134.3M | ||
| Q1 25 | $65.0M | $128.2M | ||
| Q4 24 | $-58.0M | $174.2M | ||
| Q3 24 | $12.2M | $147.9M | ||
| Q2 24 | $38.0M | $158.6M | ||
| Q1 24 | $20.0M | $147.6M |
自由现金流MAGNRVTY
| Q4 25 | $-13.0M | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $42.0M | $112.2M | ||
| Q4 24 | $-74.0M | $149.8M | ||
| Q3 24 | $3.6M | $125.6M | ||
| Q2 24 | $23.0M | $136.6M | ||
| Q1 24 | $12.5M | $129.7M |
自由现金流率MAGNRVTY
| Q4 25 | -1.6% | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 5.1% | 16.9% | ||
| Q4 24 | -10.5% | 20.5% | ||
| Q3 24 | 1.1% | 18.4% | ||
| Q2 24 | 4.1% | 19.7% | ||
| Q1 24 | 2.2% | 20.0% |
资本支出强度MAGNRVTY
| Q4 25 | 1.9% | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 2.3% | 3.4% | ||
| Q3 24 | 2.6% | 3.3% | ||
| Q2 24 | 2.7% | 3.2% | ||
| Q1 24 | 1.3% | 2.7% |
现金转化率MAGNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 2.00× | 2.87× | ||
| Q1 24 | 1.43× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
